Irina Rebin

Prix à l'honneur

JUVE Awards 2023

Law firm of the year for IP Law

Irina is member of the Practice Area Patents Technology & Life Sciences and the Life Sciences & Healthcare Industry Group. Her practice includes advising pharmaceutical, medical device, and biotechnology companies and investors on all regulatory matters throughout the entire life cycle of medicinal products, medical devices, and IVDs: from preclinical research and clinical trials, manufacturing, and market access to distribution (including post-market surveillance).

She also provides legal advice on genetic engineering, food (including food supplements), and cosmetics. Irina complements this practice focus by drafting and negotiating corresponding industry-specific agreements (including research and development agreements, license agreements, clinical trial agreements, contract/manufacturing and distribution agreements (including quality agreements)) and by advising on (cross-border) transactions in the healthcare sector.

CV

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Carrière

Since 2025 Salary Partner, Taylor Wessing

2020 - 2024 Associate/ Senior Associate

2020 Lawyer at a public corporation in the healthcare sector

Formation

2019 Second state examination, Munich

2014 – 2017 Doctoral studies at Ludwig Maximilians University Munich

2014 - 2015 Doctoral studies at Georg August University Göttingen

Publications

§§ 40-42e AMG in: Rehmann, AMG, 6. Aufl. [in Bearb./vor. Anfang 2026] § 15 Entwicklung des Arzneimittelprüfrechts

§ 16 Grundlagen klinischer Arzneimittelprüfungen

§ 17 Zentrale Voraussetzungen klinischer Prüfungen im Überblick in: Spickhoff/Handorn: Handbuch Medizinisches Forschungsrecht, C. H. Beck, München, 2023

§ 2 ProdHaftG im Beck-Online-Großkommentar (seit 2015)

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Featured

Actualités et publications récentes

View Irina's insights

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

Clinical trials in the pharmaceutical area: tips and tricks for CTA negotiations | Coffee Break Life Sciences Start-ups #7

18 juillet 2024

par Irina Rebin

Sciences de la vie et Santé

R&D Collaborations | Coffee Break Life Sciences Start-ups #4

18 avril 2024

In-depth analysis

par Irina Rebin

Cliquer ici pour en savoir plus

Sciences de la vie et Santé

Germany as a location for pharmaceutical businesses - quo vadis, 2024?

Strategy paper by the German Federal Government on improving the regulatory framework for the pharmaceutical industry in Germany

11 janvier 2024

In-depth analysis

par Irina Rebin

Cliquer ici pour en savoir plus

Irina Rebin

JUVE Awards 2023

Expertise

Services et Groupes

Secteurs

CV

Carrière

Formation

Publications

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Actualités et publications récentes

Clinical trials in the pharmaceutical area: tips and tricks for CTA negotiations | Coffee Break Life Sciences Start-ups #7

Irina Rebin

JUVE Awards 2023

Expertise

Services et Groupes

Secteurs

CV

Carrière

Formation

Publications

Langues étrangères

Prix et distinctions

JUVE Awards 2023

Actualités et publications récentes

Clinical trials in the pharmaceutical area: tips and tricks for CTA negotiations | Coffee Break Life Sciences Start-ups #7

Related news & insights

Preliminary injunctions in Poland

From small island to big impact: what Vanuatu's ICJ climate win means for business

Biotechnology as a security issue: Why dual-use control and adaptive regulation are crucial for national sustainability

AI disputes in action

When intelligent systems fail: a case study in AI liability and the future of commercial disputes

EU Deforestation Regulation (EUDR) – Proposed amendments to reduce bureaucratic burden

Draft Bill on the Implementation of the EU Environmental Criminal Law Directive

EU Parliament rejects trilogue negotiations on the Omnibus Package

Amendment of the CBAM Regulation: Simplifications and Exemptions for Companies

German Batteries Implementation Act and the Automotive Industry – Essential Insights (Part 2) | TWheel

Autres avocats qui pourraient vous intéresser

Rendez-vous à